177Lu-Dotatate for midgut neuroendocrine tumours
177Lu-Dotatate for midgut neuroendocrine tumours
About this item
Full title
177Lu-Dotatate for midgut neuroendocrine tumours
Author / Creator
Publisher
England: Elsevier Ltd
Journal title
The lancet oncology, 2017-02, Vol.18 (2), p.e74-e74
Language
English
Formats
Publication information
Publisher
England: Elsevier Ltd
Subjects
More information
Scope and Contents
Contents
Treatment with lutetium-177-Dotatate (177Lu-Dotatate) is associated with significantly longer progression-free survival compared with octreotide alone for patients with metastatic somatostatin-receptor positive midgut neuroendocrine tumours, according to a new study.
Alternative Titles
Full title
177Lu-Dotatate for midgut neuroendocrine tumours
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1868325458
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1868325458
Other Identifiers
ISSN
1470-2045
E-ISSN
1474-5488
DOI
10.1016/S1470-2045(17)30042-6
